Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan Combined With Enlonstobart in Platinum-Resistant Recurrent Ovarian Cancer
NCT07591831Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules, Lipid-based Nanoparticles, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of PBI-1308 and nanoliposomal irinotecan in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
PBI-1308nanoliposomal irinotecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07591831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591831.